UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

Gleeson, M; Hawkes, EA; Cunningham, D; Chadwick, N; Counsell, N; Lawrie, A; Jack, A; ... Linch, D; + view all (2016) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. British Journal of Haematology , 175 (4) pp. 668-672. 10.1111/bjh.14287. Green open access

[img]
Preview
Text
Counsell_PMBL manuscript British Journal of Haematology revised.pdf - ["content_typename_Accepted version" not defined]

Download (306kB) | Preview

Abstract

We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.

Type: Article
Title: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/bjh.14287
Publisher version: http://doi.org/10.1111/bjh.14287
Language: English
Additional information: © 2016 John Wiley & Sons Ltd
Keywords: Science & Technology, Life Sciences & Biomedicine, Hematology, primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone, non-Hodgkin lymphoma, clinical trials, CHEMOTHERAPY, EXPERIENCE, SCLEROSIS
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: http://discovery.ucl.ac.uk/id/eprint/1545223
Downloads since deposit
105Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item